Unlock stock picks and a broker-level newsfeed that powers Wall Street.

High Growth Tech Stocks In Australia For March 2025

In This Article:

As the Australian market navigates a turbulent period marked by global trade tensions and fluctuating indices, investors are keeping a keen eye on high-growth tech stocks that have the potential to thrive amid economic uncertainties. In this environment, identifying promising tech companies involves looking for those with innovative solutions and strong adaptability to shifting market dynamics, making them well-positioned to capitalize on emerging opportunities.

Top 10 High Growth Tech Companies In Australia

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

23.05%

25.80%

★★★★★☆

Telix Pharmaceuticals

20.02%

34.25%

★★★★★★

Gratifii

42.14%

113.99%

★★★★★★

Pro Medicus

22.56%

23.74%

★★★★★★

WiseTech Global

20.48%

25.55%

★★★★★★

BlinkLab

65.54%

64.35%

★★★★★★

Wrkr

51.62%

116.83%

★★★★★★

AVA Risk Group

29.15%

108.15%

★★★★★★

SiteMinder

21.12%

65.36%

★★★★★★

Opthea

58.62%

66.94%

★★★★★★

Click here to see the full list of 51 stocks from our ASX High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Clinuvel Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$575.89 million.

Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, amounting to A$91.02 million. The company focuses on developing and commercializing treatments for various disorders across multiple regions.

Clinuvel Pharmaceuticals has demonstrated robust growth, with its recent half-year earnings showing a revenue increase to AUD 43.29 million from AUD 35.73 million and net income rising to AUD 14.08 million from AUD 10.94 million year-over-year. This performance is underpinned by a strategic pivot towards prioritizing core projects like SCENESSE® therapy, which is expected to drive market penetration significantly. With an anticipated annual revenue growth of 23% and earnings growth of 25.8%, Clinuvel is outpacing the broader Australian market's growth rates of 6% and 12.2%, respectively, highlighting its potential in a competitive biotech landscape despite challenging economic conditions.

ASX:CUV Earnings and Revenue Growth as at Mar 2025
ASX:CUV Earnings and Revenue Growth as at Mar 2025

Infomedia

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Infomedia Ltd is a technology company that develops and supplies electronic parts catalogues, service quoting software, and e-commerce solutions for the automotive industry worldwide, with a market cap of A$464.67 million.